ArticleFrontiers in plant science2018
Development of Wheat With Hypoimmunogenic Gluten Obstructed by the Gene Editing Policy in Europe.
Article in Frontiers in plant science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 60 citations in OpenAlex.
- Innate immune dysregulation in celiac disease and refractory celiac disease: mechanisms, management and emerging therapies.Frontiers in immunology · 2026Review
- Is There a Future Without Gluten Restrictions for Celiac Patients? Update on Current Treatments.Nutrients · 2025Review
- The decision to purchase genome edited food products by Iranian consumers: theory of planned behavior as a social intervention tool.Frontiers in genome editing · 2025Article
- Processes for regulating genetically modified and gene edited plants.GM crops & food · 2023Review
- Prospects for developing allergen-depleted food crops.The plant genome · 2023Review
- Capturing Wheat Phenotypes at the Genome Level.Frontiers in plant science · 2022Review
- Current Status and Perspectives on the Application of CRISPR/Cas9 Gene-Editing System to Develop a Low-Gluten, Non-Transgenic Wheat Variety.Foods (Basel, Switzerland) · 2021Review
- Expert opinions on the regulation of plant genome editing.Plant biotechnology journal · 2021Review
- CRISPR/Cas systems: opportunities and challenges for crop breeding.Plant cell reports · 2021Review
- Genetically modified crop regulations: scope and opportunity using the CRISPR-Cas9 genome editing approach.Molecular biology reports · 2021Review
- Wheat ATIs: Characteristics and Role in Human Disease.Frontiers in nutrition · 2021Review
- The Gluten Gene: Unlocking the Understanding of Gluten Sensitivity and Intolerance.The application of clinical genetics · 2021Review
- Applications and Major Achievements of Genome Editing in Vegetable Crops: A Review.Frontiers in plant science · 2021Review
- Genome editing with the CRISPR-Cas system: an art, ethics and global regulatory perspective.Plant biotechnology journal · 2020Review
- Molecular Properties and New Potentials of Plant Nepenthesins.Plants (Basel, Switzerland) · 2020Review
- CRISPR/Cas9 Gene Editing of Gluten in Wheat to Reduce Gluten Content and Exposure-Reviewing Methods to Screen for Coeliac Safety.Frontiers in nutrition · 2020Review
- Recent Progress and Recommendations on Celiac Disease From the Working Group on Prolamin Analysis and Toxicity.Frontiers in nutrition · 2020Review
- Outlook for coeliac disease patients: towards bread wheat with hypoimmunogenic gluten by gene editing of α- and γ-gliadin gene families.BMC plant biology · 2019Article
- Protein Digestibility of Cereal Products.Foods (Basel, Switzerland) · 2019Article
- In the name of the rose: a roadmap for rose research in the genome era.Horticulture research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coeliac Disease (CD) is an auto-immune reaction to gluten in 1-2% of the human population. A gluten-free (GF) diet, excluding wheat, barley, and rye, is the only remedy. This diet is difficult to adhere to, partly because wheat gluten is added to many processed products for their viscoelastic properties. In addition, GF products are less healthy and expensive. Wheat products containing only hypoimmunogenic gluten proteins would be a desirable option. Various gluten peptides that trigger CD have been characterized. A single wheat variety contains around hundred gluten genes, producing proteins with varying numbers of epitopes. Gene editing using CRISPR/Cas9 can precisely remove or modify the DNA sequences coding for immunogenic peptides. Wheat with hypoimmunogenic gluten thus exemplifies the potential of gene editing for improving crops for human consumption where conventional breeding cannot succeed. We describe here, in relation to breeding hypoimmunogenic wheat varieties, the inconsistencies of applying GM regulation in Europe for gene-edited plants while mutation breeding-derived plants are exempted. We explain that healthy products derived from this new technology may become available in the United States, Canada, Argentina and other countries but not in Europe, because of strict regulation of unintended GM risk at the expense of reduction the existing immunogenicity risks of patients. We argue that regulation of gene-edited plants should be based on scientific evidence. Therefore, we strongly recommend implementing the innovation principle. Responsible Research and Innovation, involving stakeholders including CD patient societies in the development of gene-editing products, will enable progress toward healthy products and encourage public acceptance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.